Prenatal diagnosis · 2025
Diagnostic Value of Cell-Free DNA Fetal Fraction in Patients With Prenatally Suspected Placenta Accreta Spectrum Disorder.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Chirumbole Danielle, Parobek Christian M, Tai Alex, Sangi-Haghpeykar Haleh, Mendez Yamely H, Kamepalli Spoorthi, Reed Christina C, Ladron de Guevara Arthur, Lane Keneshia, Hoppenot Claire, Shamshirsaz Amir A, Belfort Michael A, Munoz Jessian L, Lombaard Hendrik A
Аннотация
OBJECTIVE: The purpose of this study was to investigate the relationship between fetal fraction (FF) and placenta accreta spectrum (PAS) pathology in patients with prenatally suspected PAS.
METHODS: This was a case-control study utilizing a database of pregnancies with suspected or proven PAS delivered between 6/2012 and 7/2024 at a single institution. Pregnancies were excluded if FF was not reported. The primary outcome was mean FF in pregnancies with a final clinical diagnosis of low FIGO grade (no PAS or FIGO1-2) versus high FIGO grade (FIGO3) placenta accreta. Results were reported as mean FF ± standard error of the mean. Adjusted means were also reported after assessing confounders.
RESULTS: Of the 468 pregnancies assessed, 128 met the full inclusion criteria. While the unadjusted mean FF in the low-grade group did not differ from the high-grade group (9.6% ± 0.49, n = 81 vs. 10.7% ± 0.64, n = 47; p = 0.22), the adjusted mean FF in the low-grade group was significantly lower than that in the high-grade group (9.3% ± 0.48 vs. 11.1% ± 0.64; p = 0.03).
CONCLUSIONS: While FF alone is unlikely to be clinically useful in predicting PAS pathology, NIPT results have the potential to improve the diagnostic precision of other clinical tools for PAS prediction.
METHODS: This was a case-control study utilizing a database of pregnancies with suspected or proven PAS delivered between 6/2012 and 7/2024 at a single institution. Pregnancies were excluded if FF was not reported. The primary outcome was mean FF in pregnancies with a final clinical diagnosis of low FIGO grade (no PAS or FIGO1-2) versus high FIGO grade (FIGO3) placenta accreta. Results were reported as mean FF ± standard error of the mean. Adjusted means were also reported after assessing confounders.
RESULTS: Of the 468 pregnancies assessed, 128 met the full inclusion criteria. While the unadjusted mean FF in the low-grade group did not differ from the high-grade group (9.6% ± 0.49, n = 81 vs. 10.7% ± 0.64, n = 47; p = 0.22), the adjusted mean FF in the low-grade group was significantly lower than that in the high-grade group (9.3% ± 0.48 vs. 11.1% ± 0.64; p = 0.03).
CONCLUSIONS: While FF alone is unlikely to be clinically useful in predicting PAS pathology, NIPT results have the potential to improve the diagnostic precision of other clinical tools for PAS prediction.